LinkedIn Profile

Access Atlas Genetics historical Linkedin company profile data on number of followers, employee headcount and more
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal GICS Sector GICS Industry
private:atlasgenetics 432154 Nov 18th, 2019 12:00AM Atlas Genetics 1.1K 19.00 Open Medical Device Nov 18th, 2019 03:46PM Nov 18th, 2019 03:46PM Atlas Genetics is creating a new category of in vitro diagnostics focused on decentralized, near-­patient and Point-­of-­Care (POC) testing for everyone. With routine testing rapidly moving from the “hub” to the “spokes,” Atlas’s io® platform is poised to benefit from this growing trend in decentralized testing. The company’s proprietary technology platform positions Atlas in the vanguard of the rapidly evolving and increasingly patient-directed landscape of consumer diagnostics, where convenience, rapid “test and treat,” and portability of platform are becoming critical to success. Atlas aims to meet patients where they are and improve patient outcomes by arming healthcare professionals with a simple-­to-­use, rapid and cost-­effective solution for on-­demand diagnosis of infectious diseases. A sample-answer time of 30 mins, high accuracy and low cost are hallmarks of the company’s broad platform for a broad range of infectious diseases. Atlas Genetics’ investors include Novartis Venture Fund, Consort Medical, Wondfo Biotech, LSP Venture Capital, BB Biotech, Johnson & Johnson Innovation, RMI Investments and Southwest Ventures Fund. Atlas Genetics is a global company and has locations in Boston, MA and Bath UK. For further information visit www.atlasgenetics.com. Open Point-of-care in vitro diagnostic test development, Electrochemical detection, Instrumentation development, Micro-fluidic device development Open 77 N Washington St Boston Massachusetts US 02114 Health Care Pharmaceuticals & Biotechnology
private:atlasgenetics 432154 Nov 16th, 2019 12:00AM Atlas Genetics 1.1K 19.00 Open Medical Device Nov 16th, 2019 03:57PM Nov 16th, 2019 03:57PM Atlas Genetics is creating a new category of in vitro diagnostics focused on decentralized, near-­patient and Point-­of-­Care (POC) testing for everyone. With routine testing rapidly moving from the “hub” to the “spokes,” Atlas’s io® platform is poised to benefit from this growing trend in decentralized testing. The company’s proprietary technology platform positions Atlas in the vanguard of the rapidly evolving and increasingly patient-directed landscape of consumer diagnostics, where convenience, rapid “test and treat,” and portability of platform are becoming critical to success. Atlas aims to meet patients where they are and improve patient outcomes by arming healthcare professionals with a simple-­to-­use, rapid and cost-­effective solution for on-­demand diagnosis of infectious diseases. A sample-answer time of 30 mins, high accuracy and low cost are hallmarks of the company’s broad platform for a broad range of infectious diseases. Atlas Genetics’ investors include Novartis Venture Fund, Consort Medical, Wondfo Biotech, LSP Venture Capital, BB Biotech, Johnson & Johnson Innovation, RMI Investments and Southwest Ventures Fund. Atlas Genetics is a global company and has locations in Boston, MA and Bath UK. For further information visit www.atlasgenetics.com. Open Point-of-care in vitro diagnostic test development, Electrochemical detection, Instrumentation development, Micro-fluidic device development Open 77 N Washington St Boston Massachusetts US 02114 Health Care Pharmaceuticals & Biotechnology
private:atlasgenetics 432154 Nov 15th, 2019 12:00AM Atlas Genetics 1.1K 19.00 Open Medical Device Nov 15th, 2019 12:39PM Nov 15th, 2019 12:39PM Atlas Genetics is creating a new category of in vitro diagnostics focused on decentralized, near-­patient and Point-­of-­Care (POC) testing for everyone. With routine testing rapidly moving from the “hub” to the “spokes,” Atlas’s io® platform is poised to benefit from this growing trend in decentralized testing. The company’s proprietary technology platform positions Atlas in the vanguard of the rapidly evolving and increasingly patient-directed landscape of consumer diagnostics, where convenience, rapid “test and treat,” and portability of platform are becoming critical to success. Atlas aims to meet patients where they are and improve patient outcomes by arming healthcare professionals with a simple-­to-­use, rapid and cost-­effective solution for on-­demand diagnosis of infectious diseases. A sample-answer time of 30 mins, high accuracy and low cost are hallmarks of the company’s broad platform for a broad range of infectious diseases. Atlas Genetics’ investors include Novartis Venture Fund, Consort Medical, Wondfo Biotech, LSP Venture Capital, BB Biotech, Johnson & Johnson Innovation, RMI Investments and Southwest Ventures Fund. Atlas Genetics is a global company and has locations in Boston, MA and Bath UK. For further information visit www.atlasgenetics.com. Open Point-of-care in vitro diagnostic test development, Electrochemical detection, Instrumentation development, Micro-fluidic device development Open 77 N Washington St Boston Massachusetts US 02114 Health Care Pharmaceuticals & Biotechnology
private:atlasgenetics 432154 Nov 14th, 2019 12:00AM Atlas Genetics 1.1K 19.00 Open Medical Device Nov 14th, 2019 05:55PM Nov 14th, 2019 05:55PM Atlas Genetics is creating a new category of in vitro diagnostics focused on decentralized, near-­patient and Point-­of-­Care (POC) testing for everyone. With routine testing rapidly moving from the “hub” to the “spokes,” Atlas’s io® platform is poised to benefit from this growing trend in decentralized testing. The company’s proprietary technology platform positions Atlas in the vanguard of the rapidly evolving and increasingly patient-directed landscape of consumer diagnostics, where convenience, rapid “test and treat,” and portability of platform are becoming critical to success. Atlas aims to meet patients where they are and improve patient outcomes by arming healthcare professionals with a simple-­to-­use, rapid and cost-­effective solution for on-­demand diagnosis of infectious diseases. A sample-answer time of 30 mins, high accuracy and low cost are hallmarks of the company’s broad platform for a broad range of infectious diseases. Atlas Genetics’ investors include Novartis Venture Fund, Consort Medical, Wondfo Biotech, LSP Venture Capital, BB Biotech, Johnson & Johnson Innovation, RMI Investments and Southwest Ventures Fund. Atlas Genetics is a global company and has locations in Boston, MA and Bath UK. For further information visit www.atlasgenetics.com. Open Point-of-care in vitro diagnostic test development, Electrochemical detection, Instrumentation development, Micro-fluidic device development Open 77 N Washington St Boston Massachusetts US 02114 Health Care Pharmaceuticals & Biotechnology
private:atlasgenetics 432154 Nov 13th, 2019 12:00AM Atlas Genetics 1.1K 19.00 Open Medical Device Nov 13th, 2019 01:07PM Nov 13th, 2019 01:07PM Atlas Genetics is creating a new category of in vitro diagnostics focused on decentralized, near-­patient and Point-­of-­Care (POC) testing for everyone. With routine testing rapidly moving from the “hub” to the “spokes,” Atlas’s io® platform is poised to benefit from this growing trend in decentralized testing. The company’s proprietary technology platform positions Atlas in the vanguard of the rapidly evolving and increasingly patient-directed landscape of consumer diagnostics, where convenience, rapid “test and treat,” and portability of platform are becoming critical to success. Atlas aims to meet patients where they are and improve patient outcomes by arming healthcare professionals with a simple-­to-­use, rapid and cost-­effective solution for on-­demand diagnosis of infectious diseases. A sample-answer time of 30 mins, high accuracy and low cost are hallmarks of the company’s broad platform for a broad range of infectious diseases. Atlas Genetics’ investors include Novartis Venture Fund, Consort Medical, Wondfo Biotech, LSP Venture Capital, BB Biotech, Johnson & Johnson Innovation, RMI Investments and Southwest Ventures Fund. Atlas Genetics is a global company and has locations in Boston, MA and Bath UK. For further information visit www.atlasgenetics.com. Open Point-of-care in vitro diagnostic test development, Electrochemical detection, Instrumentation development, Micro-fluidic device development Open 77 N Washington St Boston Massachusetts US 02114 Health Care Pharmaceuticals & Biotechnology
private:atlasgenetics 432154 Nov 12th, 2019 12:00AM Atlas Genetics 1.1K 19.00 Open Medical Device Nov 12th, 2019 02:49PM Nov 12th, 2019 02:49PM Atlas Genetics is creating a new category of in vitro diagnostics focused on decentralized, near-­patient and Point-­of-­Care (POC) testing for everyone. With routine testing rapidly moving from the “hub” to the “spokes,” Atlas’s io® platform is poised to benefit from this growing trend in decentralized testing. The company’s proprietary technology platform positions Atlas in the vanguard of the rapidly evolving and increasingly patient-directed landscape of consumer diagnostics, where convenience, rapid “test and treat,” and portability of platform are becoming critical to success. Atlas aims to meet patients where they are and improve patient outcomes by arming healthcare professionals with a simple-­to-­use, rapid and cost-­effective solution for on-­demand diagnosis of infectious diseases. A sample-answer time of 30 mins, high accuracy and low cost are hallmarks of the company’s broad platform for a broad range of infectious diseases. Atlas Genetics’ investors include Novartis Venture Fund, Consort Medical, Wondfo Biotech, LSP Venture Capital, BB Biotech, Johnson & Johnson Innovation, RMI Investments and Southwest Ventures Fund. Atlas Genetics is a global company and has locations in Boston, MA and Bath UK. For further information visit www.atlasgenetics.com. Open Point-of-care in vitro diagnostic test development, Electrochemical detection, Instrumentation development, Micro-fluidic device development Open 77 N Washington St Boston Massachusetts US 02114 Health Care Pharmaceuticals & Biotechnology
private:atlasgenetics 432154 Nov 11th, 2019 12:00AM Atlas Genetics 1.1K 19.00 Open Medical Device Nov 11th, 2019 02:47PM Nov 11th, 2019 02:47PM Atlas Genetics is creating a new category of in vitro diagnostics focused on decentralized, near-­patient and Point-­of-­Care (POC) testing for everyone. With routine testing rapidly moving from the “hub” to the “spokes,” Atlas’s io® platform is poised to benefit from this growing trend in decentralized testing. The company’s proprietary technology platform positions Atlas in the vanguard of the rapidly evolving and increasingly patient-directed landscape of consumer diagnostics, where convenience, rapid “test and treat,” and portability of platform are becoming critical to success. Atlas aims to meet patients where they are and improve patient outcomes by arming healthcare professionals with a simple-­to-­use, rapid and cost-­effective solution for on-­demand diagnosis of infectious diseases. A sample-answer time of 30 mins, high accuracy and low cost are hallmarks of the company’s broad platform for a broad range of infectious diseases. Atlas Genetics’ investors include Novartis Venture Fund, Consort Medical, Wondfo Biotech, LSP Venture Capital, BB Biotech, Johnson & Johnson Innovation, RMI Investments and Southwest Ventures Fund. Atlas Genetics is a global company and has locations in Boston, MA and Bath UK. For further information visit www.atlasgenetics.com. Open Point-of-care in vitro diagnostic test development, Electrochemical detection, Instrumentation development, Micro-fluidic device development Open 77 N Washington St Boston Massachusetts US 02114 Health Care Pharmaceuticals & Biotechnology
private:atlasgenetics 432154 Nov 10th, 2019 12:00AM Atlas Genetics 1.1K 20.00 Open Medical Device Nov 10th, 2019 05:54PM Nov 10th, 2019 05:54PM Atlas Genetics is creating a new category of in vitro diagnostics focused on decentralized, near-­patient and Point-­of-­Care (POC) testing for everyone. With routine testing rapidly moving from the “hub” to the “spokes,” Atlas’s io® platform is poised to benefit from this growing trend in decentralized testing. The company’s proprietary technology platform positions Atlas in the vanguard of the rapidly evolving and increasingly patient-directed landscape of consumer diagnostics, where convenience, rapid “test and treat,” and portability of platform are becoming critical to success. Atlas aims to meet patients where they are and improve patient outcomes by arming healthcare professionals with a simple-­to-­use, rapid and cost-­effective solution for on-­demand diagnosis of infectious diseases. A sample-answer time of 30 mins, high accuracy and low cost are hallmarks of the company’s broad platform for a broad range of infectious diseases. Atlas Genetics’ investors include Novartis Venture Fund, Consort Medical, Wondfo Biotech, LSP Venture Capital, BB Biotech, Johnson & Johnson Innovation, RMI Investments and Southwest Ventures Fund. Atlas Genetics is a global company and has locations in Boston, MA and Bath UK. For further information visit www.atlasgenetics.com. Open Point-of-care in vitro diagnostic test development, Electrochemical detection, Instrumentation development, Micro-fluidic device development Open 77 N Washington St Boston Massachusetts US 02114 Health Care Pharmaceuticals & Biotechnology
private:atlasgenetics 432154 Nov 9th, 2019 12:00AM Atlas Genetics 1.1K 20.00 Open Medical Device Nov 9th, 2019 05:21PM Nov 9th, 2019 05:21PM Atlas Genetics is creating a new category of in vitro diagnostics focused on decentralized, near-­patient and Point-­of-­Care (POC) testing for everyone. With routine testing rapidly moving from the “hub” to the “spokes,” Atlas’s io® platform is poised to benefit from this growing trend in decentralized testing. The company’s proprietary technology platform positions Atlas in the vanguard of the rapidly evolving and increasingly patient-directed landscape of consumer diagnostics, where convenience, rapid “test and treat,” and portability of platform are becoming critical to success. Atlas aims to meet patients where they are and improve patient outcomes by arming healthcare professionals with a simple-­to-­use, rapid and cost-­effective solution for on-­demand diagnosis of infectious diseases. A sample-answer time of 30 mins, high accuracy and low cost are hallmarks of the company’s broad platform for a broad range of infectious diseases. Atlas Genetics’ investors include Novartis Venture Fund, Consort Medical, Wondfo Biotech, LSP Venture Capital, BB Biotech, Johnson & Johnson Innovation, RMI Investments and Southwest Ventures Fund. Atlas Genetics is a global company and has locations in Boston, MA and Bath UK. For further information visit www.atlasgenetics.com. Open Point-of-care in vitro diagnostic test development, Electrochemical detection, Instrumentation development, Micro-fluidic device development Open 77 N Washington St Boston Massachusetts US 02114 Health Care Pharmaceuticals & Biotechnology
private:atlasgenetics 432154 Nov 8th, 2019 12:00AM Atlas Genetics 1.1K 20.00 Open Medical Device Nov 8th, 2019 02:32PM Nov 8th, 2019 02:32PM Atlas Genetics is creating a new category of in vitro diagnostics focused on decentralized, near-­patient and Point-­of-­Care (POC) testing for everyone. With routine testing rapidly moving from the “hub” to the “spokes,” Atlas’s io® platform is poised to benefit from this growing trend in decentralized testing. The company’s proprietary technology platform positions Atlas in the vanguard of the rapidly evolving and increasingly patient-directed landscape of consumer diagnostics, where convenience, rapid “test and treat,” and portability of platform are becoming critical to success. Atlas aims to meet patients where they are and improve patient outcomes by arming healthcare professionals with a simple-­to-­use, rapid and cost-­effective solution for on-­demand diagnosis of infectious diseases. A sample-answer time of 30 mins, high accuracy and low cost are hallmarks of the company’s broad platform for a broad range of infectious diseases. Atlas Genetics’ investors include Novartis Venture Fund, Consort Medical, Wondfo Biotech, LSP Venture Capital, BB Biotech, Johnson & Johnson Innovation, RMI Investments and Southwest Ventures Fund. Atlas Genetics is a global company and has locations in Boston, MA and Bath UK. For further information visit www.atlasgenetics.com. Open Point-of-care in vitro diagnostic test development, Electrochemical detection, Instrumentation development, Micro-fluidic device development Open 77 N Washington St Boston Massachusetts US 02114 Health Care Pharmaceuticals & Biotechnology

Request a demo to view additional historical data, and much more.

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.